Refine by
Patient Identification Articles & Analysis
24 news found
Beyond academic research and transplantation applications, CD Genomics' HLA typing solutions hold great promise in pharmaceutical drug development. They facilitate the identification of patient cohorts with specific HLA alleles, essential for developing targeted therapies. ...
” Cellworks Precision Drug Development: Clinical Stage Clinical Trial Biosimulation: By biosimulating clinical trials, the Cellworks Platform may be able to predict human clinical response to pharmaceutical agents in just weeks, delivering critical insights years ahead of a traditional clinical trial. Patient cohorts are selected from the Cellworks ...
“As we continue to expand our clinical research program, we’re looking forward to improving our trial recruitment efforts with more accurate patient screening and identification, and ultimately, increasing patient access to trials and care.” The partnership will allow Gastro Health physicians to leverage Iterative ...
Geneva, Switzerland – October 26th, 2022, STALICLA SA, a precision neuroscience clinical stage biotech, advancing the first precision medicine platform (DEPI) for patients with Neurodevelopmental Disorders (NDDs), today announced first patient visits in its new STA-B-001 clinical observational-biosampling study in Spain and USA. ...
BySTALICLA
Medical Director Jay Pathmanathan, MD, PhD, discussed how the company has applied its machine learning platform to standard electroencephalography (EEG) data to detect electrical disturbances in the brain that may predict cognitive decline and explain variability in disease course for patients with Alzheimer's disease. Pathmanathan's presentation focused on research he ...
Cost is the main reason to avoid or stop insulin pump usage, emphasising the importance of patient-centric reimbursement policies for diabetes patients. Managing Type 1 diabetes takes considerable time and effort, and the healthcare stakeholders should not overlook the burden of care on patients’ quality of life. ...
Cerapedics, a private ortho-biologics company, today announced that results from a clinical trial evaluating i-FACTOR Peptide Enhanced Bone Graft in non-instrumented lumbar fusion surgery has been published in the May 2020, Volume 20, Issue 5 print of The Spine Journal as the lead article. The data demonstrate that elderly patients in Denmark treated with i-FACTOR bone graft plus local bone had a ...
Synchron and Mount Sinai Hospital in New York Advance Industry-First FDA-Approved Clinical Trial for Brain-Computer Interface in U.S. Paralysis is a devastating condition for more than 5 million patients in the United States Synchron, an endovascular brain-computer (BCI) interface company, today announced the enrollment of the first patient in the US clinical trial, COMMAND, for patients ...
As new lumbar spinal stenosis (LSS) procedures become available, practices are evolving the way they collaborate and work together to optimize patient care. The mild® Procedure’s patient selection process is quite simple, but requires imaging review, which is often not a part of Advanced Practice Providers’ (APP) traditional education. ...
Anteris Technologies Ltd (ASX: AVR) reports the first-in-human DurAVR™ THV study met or exceeded its interim study objectives. At the 30-day follow up point, the first five patients of the planned 10-patient study showed: All five subjects continued to do well with no reported adverse events (no death, stroke, myocardial infarction, reintervention). An average 86% improvement in mean ...
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today provided a general corporate update. 2021 Highlights Implanted first U.S. patient in the DREAM IDE pivotal study in December 2020; there are currently ...
Infraredx, a Nipro Company, a pioneer in intravascular imaging for mapping coronary artery disease, announced today the enrollment of the first patient in its EXPANSE PTCA study (NCT04985773) at the Cardiology Associates of North Mississippi in Tupelo, Mississippi. The study will be conducted in the United States with the objective to evaluate safety and effectiveness of the ...
Cerapedics Inc., a private ortho-biologics company dedicated to enhancing the science of bone repair, announced today that results of a study to evaluate the cost-effectiveness of i-FACTOR Peptide Enhanced Bone Graft compared to autograft for patients undergoing ACDF surgery were recently published in ClinicoEconomics and Outcomes Research (July 2021, Volume 2021, Issue 13). In this landmark ...
In addition to the new website, the Company has introduced updated tools, guidance, and training materials to assist in identifying prospective patients for ReActiv8 therapy, educating physicians on the ReActiv8 system and becoming ReActiv8-certified, and helping patients access ReActiv8 in the U.S. Specific resources include physician training protocols and ...
Endospan, a pioneer in off-the-shelf endovascular repair of aortic arch disease, announces the first implant of the NEXUS™ Aortic Arch Stent Graft System on a patient with a thoracic aortic aneurysm as part of the TRIOMPHE Study in Norfolk, Virginia, January 11, 2021. The TRIOMPHE Study is a multi-arm, multi-center, non-randomized, prospective, clinical study to evaluate the safety and ...
Cerapedics, a private ortho-biologics company, today announced the Health Canada approval of the company’s next-generation bone graft called i-FACTOR+ Matrix, making it the first market to approve the commercial launch of this product. “We are excited to announce Canadian regulatory approval of our next-generation product, based on P15 osteogenic cell-binding peptide , i-FACTOR+ ...
The assay is capable of detecting minute amounts of virus presence, allowing for identification of patients at the early stages of infection and reducing false negative results, an important leverage when working to contain the spread of the virus. ...
Throughout this week Longenesis will be intensively working with mentors and investors (including Skype and Bolt co-Founders) to create and validate a concept for post-COVID-19 data utilization for research, faster drug development and patient recruitment. We believe that the tools developed by Longenesis have found a perfect fit in solving challenges in data and ...
The selected compound will be developed using a theranostic approach, a combination of diagnostic and therapeutic features with the same compound, allowing the pre-identification of patients who have the receptors necessary to respond to the targeted radiotherapy. ...
V-Wave Ltd., a privately held medical device company developing novel implantable interatrial shunt devices, today announced that the U.S. Food and Drug Administration (FDA) has just granted the company a Breakthrough Device Designation for its interatrial shunt for Heart Failure (HF). V-Wave’s minimally invasive, implanted interatrial shunt is being evaluated in a global, randomized, ...